KR100794610B1 - 디벤조-p-디옥신 유도체를 유효성분으로 하는 암 예방 및치료용 조성물 및 이를 함유하는 건강보조식품 - Google Patents
디벤조-p-디옥신 유도체를 유효성분으로 하는 암 예방 및치료용 조성물 및 이를 함유하는 건강보조식품 Download PDFInfo
- Publication number
- KR100794610B1 KR100794610B1 KR1020060086706A KR20060086706A KR100794610B1 KR 100794610 B1 KR100794610 B1 KR 100794610B1 KR 1020060086706 A KR1020060086706 A KR 1020060086706A KR 20060086706 A KR20060086706 A KR 20060086706A KR 100794610 B1 KR100794610 B1 KR 100794610B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- formula
- dibenzo
- ecklonia
- cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 163
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 83
- 201000011510 cancer Diseases 0.000 title claims abstract description 62
- NFBOHOGPQUYFRF-UHFFFAOYSA-N oxanthrene Chemical class C1=CC=C2OC3=CC=CC=C3OC2=C1 NFBOHOGPQUYFRF-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims description 8
- 235000013305 food Nutrition 0.000 title abstract description 6
- 230000002113 chemopreventative effect Effects 0.000 title 1
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 6
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 6
- 235000008429 bread Nutrition 0.000 claims abstract description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract 5
- 201000000849 skin cancer Diseases 0.000 claims abstract 5
- 150000004827 dibenzo-1,4-dioxins Chemical class 0.000 claims description 32
- 241001512723 Ecklonia Species 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 12
- 235000015872 dietary supplement Nutrition 0.000 claims description 11
- 241000230129 Eisenia <Phaeophyceae> Species 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 241000741680 Ecklonia arborea Species 0.000 claims description 5
- 241001512722 Ecklonia cava Species 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 241000243681 Eisenia bicyclis Species 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 241000946389 Ecklonia kurome Species 0.000 claims description 2
- 241000653613 Ecklonia radicosa Species 0.000 claims description 2
- 241000439005 Ecklonia stolonifera Species 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 241001392689 Ecklonia maxima Species 0.000 claims 1
- 241001122767 Theaceae Species 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical class C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 25
- 108010057466 NF-kappa B Proteins 0.000 abstract description 15
- 102000003945 NF-kappa B Human genes 0.000 abstract description 15
- 230000010261 cell growth Effects 0.000 abstract description 12
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract description 11
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract description 8
- 230000001093 anti-cancer Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000033115 angiogenesis Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract description 3
- 230000006907 apoptotic process Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000000153 supplemental effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 37
- 230000000694 effects Effects 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 230000000711 cancerogenic effect Effects 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 11
- 231100000315 carcinogenic Toxicity 0.000 description 11
- 229940094952 green tea extract Drugs 0.000 description 11
- 235000020688 green tea extract Nutrition 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 7
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 108050006400 Cyclin Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- DQEPMTIXHXSFOR-UHFFFAOYSA-N benzo[a]pyrene diol epoxide I Chemical compound C1=C2C(C3OC3C(C3O)O)=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 DQEPMTIXHXSFOR-UHFFFAOYSA-N 0.000 description 5
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 5
- 235000005487 catechin Nutrition 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229950001002 cianidanol Drugs 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 229940087603 grape seed extract Drugs 0.000 description 5
- 235000002532 grape seed extract Nutrition 0.000 description 5
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 5
- 235000008696 isoflavones Nutrition 0.000 description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229960001285 quercetin Drugs 0.000 description 5
- 235000005875 quercetin Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000002110 toxicologic effect Effects 0.000 description 5
- 231100000027 toxicology Toxicity 0.000 description 5
- 239000001717 vitis vinifera seed extract Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000199919 Phaeophyceae Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 231100000357 carcinogen Toxicity 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 150000002515 isoflavone derivatives Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004611 cancer cell death Effects 0.000 description 2
- 230000005880 cancer cell killing Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- XZPNVGKRRGOOMS-UHFFFAOYSA-N 10-methyl-5h-phenazine Chemical compound C1=CC=C2N(C)C3=CC=CC=C3NC2=C1 XZPNVGKRRGOOMS-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000011531 Quantitect SYBR Green PCR kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000475042 Stolonifera Species 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000000080 chela (arthropods) Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- -1 dihydroxyphenyl Chemical group 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
시료 | 시료의 조성 |
조성물 1 | I (R=H), 99% |
조성물 2 | II (R=H), 98% |
조성물 3 | III (R=H), 99% |
조성물 4 | IV (R=H), 99% |
조성물 5 | V (R=H), 99% |
조성물 6 | VI (R=H), 99% |
조성물 7 | VII (R=H), 99% |
조성물 8 | VIII (R=H), 99% |
조성물 9 | IX (R=H), 99% |
조성물 10 | X (R=H), 99% |
조성물 11 | II (R=H), 60% + III (R=H), 25% + IV (R=H), 15% |
조성물 12 | IV (R=H), 70% + V (R=H) 8% + VI (22%) |
조성물 13 | IV (R=H), 10% + X (R=H), 80% + VII (R=H), 10% |
조성물 14 | I (R=H), 3% + II (R=H), 60% + III (R=H), 10% + IV (R=H), 12% + V (R=H), 5% + VI (R=H), 10% |
조성물 15 | II (R=H), 60% + IV (R=H), 20% + VI (R=H), 15% + VII (R=H), 5% |
조성물 16 | IV(R=acetyl, H (3:7)) |
조성물 17 | II (R=oleoyl, H (1:9) |
조성물 18 | VI (R=methyl, H (2:8)) |
시료 | 시료의 조성 | 암세포 성장 억제 활성 (%) |
조성물 1 | I (R=H), 99% | 78 |
조성물 2 | II (R=H), 98% | 82 |
조성물 3 | III (R=H), 99% | 85 |
조성물 4 | IV (R=H), 99% | 90 |
조성물 5 | V (R=H), 99% | 74 |
조성물 6 | VI (R=H), 99% | 76 |
조성물 7 | VII (R=H), 99% | 88 |
조성물 8 | VIII (R=H), 99% | 87 |
조성물 9 | IX (R=H), 99% | 74 |
조성물 10 | X (R=H), 99% | 82 |
조성물 11 | II (R=H), 60% + III (R=H), 25% + IV (R=H), 15% | 77 |
조성물 12 | IV (R=H), 70% + V (R=H) 8% + VI (22%) | 80 |
조성물 13 | IV (R=H), 10% + X (R=H), 80% + VII (R=H), 10% | 90 |
조성물 14 | I (R=H), 3% + II (R=H), 60% + III (R=H), 10% + IV (R=H), 12% + V (R=H), 5% + VI (R=H), 10% | 89 |
조성물 15 | II (R=H), 60% + IV (R=H), 20% + VI (R=H), 15% + VII (R=H), 5% | 80 |
조성물 16 | IV(R=acetyl, H (3:7)) | 80 |
조성물 17 | II (R=oleoyl, H (1:9) | 74 |
조성물 18 | VI (R=methyl, H (2:8)) | 70 |
카테킨 | 65 | |
라스베라트롤 | 69 | |
녹차추출물 | 66 | |
포도씨 추출물 | 62 | |
케르세틴 | 50 | |
이소플라본 | 55 |
시료 | 시료의 조성 | 상대적인 NFkB 활성 | NFkB 생성 억제율(%) |
BPDE 대조군 | 6.5 | - | |
조성물 1 | I (R=H), 99% | 2.3 | 65 |
조성물 2 | II (R=H), 98% | 2.8 | 57 |
조성물 3 | III (R=H), 99% | 1.4 | 78 |
조성물 4 | IV (R=H), 99% | 1.8 | 72 |
조성물 5 | V (R=H), 99% | 1.6 | 75 |
조성물 6 | VI (R=H), 99% | 2.2 | 66 |
조성물 7 | VII (R=H), 99% | 2.6 | 60 |
조성물 8 | VIII (R=H), 99% | 2.8 | 57 |
조성물 9 | IX (R=H), 99% | 2.6 | 60 |
조성물 10 | X (R=H), 99% | 1.9 | 71 |
조성물 11 | II (R=H), 60% + III (R=H), 25% + IV (R=H), 15% | 2.0 | 69 |
조성물 12 | IV (R=H), 70% + V (R=H) 8% + VI (22%) | 1.3 | 80 |
조성물 13 | IV (R=H), 10% + X (R=H), 80% + VII (R=H), 10% | 1.7 | 74 |
조성물 14 | I (R=H), 3% + II (R=H), 60% + III (R=H), 10% + IV (R=H), 12% + V (R=H), 5% + VI (R=H), 10% | 3.2 | 51 |
조성물 15 | II (R=H), 60% + IV (R=H), 20% + VI (R=H), 15% + VII (R=H), 5% | 3.1 | 52 |
조성물 16 | IV(R=acetyl, H (3:7)) | 3.1 | 52 |
조성물 17 | II (R=oleoyl, H (1:9) | 3.2 | 51 |
조성물 18 | VI (R=methyl, H (2:8)) | 2.9 | 55 |
카테킨 | 4.0 | 38 | |
라스베라트롤 | 4.0 | 38 | |
녹차추출물 | 3.9 | 40 | |
포도씨 추출물 | 4.0 | 38 | |
케르세틴 | 3.8 | 42 | |
이소플라본 | 3.7 | 43 |
시료 | 시료의 조성 | VEGF 생성억제율(% ) (HepG2) | VEGF 생성 억제율(%) (HpLa) |
조성물 1 | I (R=H), 99% | 55 | 74 |
조성물 2 | II (R=H), 98% | 58 | 69 |
조성물 3 | III (R=H), 99% | 60 | 60 |
조성물 4 | IV (R=H), 99% | 78 | 80 |
조성물 5 | V (R=H), 99% | 77 | 49 |
조성물 6 | VI (R=H), 99% | 78 | 55 |
조성물 7 | VII (R=H), 99% | 69 | 59 |
조성물 8 | VIII (R=H), 99% | 79 | 69 |
조성물 9 | IX (R=H), 99% | 59 | 72 |
조성물 10 | X (R=H), 99% | 66 | 73 |
조성물 11 | II (R=H), 60% + III (R=H), 25% + IV (R=H), 15% | 62 | 55 |
조성물 12 | IV (R=H), 70% + V (R=H) 8% + VI (22%) | 64 | 83 |
조성물 13 | IV (R=H), 10% + X (R=H), 80% + VII (R=H), 10% | 55 | 80 |
조성물 14 | I (R=H), 3% + II (R=H), 60% + III (R=H), 10% + IV (R=H), 12% + V (R=H), 5% + VI (R=H), 10% | 49 | 59 |
조성물 15 | II (R=H), 60% + IV (R=H), 20% + VI (R=H), 15% + VII (R=H), 5% | 50 | 69 |
조성물 16 | IV(R=acetyl, H (3:7)) | 55 | 54 |
조성물 17 | II (R=oleoyl, H (1:9) | 58 | 50 |
조성물 18 | VI (R=methyl, H (2:8)) | 79 | 68 |
카테킨 | 43 | 33 | |
라스베라트롤 | 42 | 35 | |
녹차추출물 | 39 | 46 | |
포도씨 추출물 | 44 | 36 | |
케르세틴 | 38 | 42 | |
이소플라본 | 40 | 50 |
군 | 시료 | NMBA | 암 발생율 (%) | 종양의 수/마우스 | 종양의 부피(mm3)/종양 |
대조군 | - | - | - | 0 | 0 |
발암 대조군 | - | + | 100 | 8.54±0.7 | 6.43±1.4 |
실험군 1 | 조성물 3 | + | 74 | 4.73±0.4 | 2.2±0.3 |
실험군 2 | 조성물 12 | + | 72 | 3.42±0.2 | 1.8±0.2 |
비교군 | 녹차추출물 | + | 90 | 6.8±0.5 | 4.6±0.6 |
Claims (10)
- 삭제
- 청구항 2에 있어서, 상기 화학식 1 내지 10의 R이 각각 H인 것을 특징으로 하는, 피부암 이외의 암을 대상으로 하는 암 예방 또는 치료용 조성물.
- 청구항 2에 있어서, 상기 디벤조-p-디옥신 유도체로서, 조성물 전체 중량에 대하여,상기 화학식 1의 디벤조-p-디옥신 유도체 0.1-6중량%, 상기 화학식 2의 디벤조-p-디옥신 유도체 5-60중량%, 상기 화학식 3의 디벤조-p-디옥신 유도체 1-30중량%, 상기 화학식 4의 디벤조-p-디옥신 유도체 0.5-20중량%, 상기 화학식 5의 디벤조-p-디옥신 유도체 0.1-10중량%, 상기 화학식 6의 디벤조-p-디옥신 유도체 0.5-15중량%, 상기 화학식 7의 디벤조-p-디옥신 유도체 0.1-5중량%, 상기 화학식 8의 디벤조-p-디옥신 유도체 0.1-5중량%, 상기 화학식 9의 디벤조-p-디옥신 유도체 0.1-10중량% 및 상기 화학식 10의 디벤조-p-디옥신 유도체 0.1-12중량%으로 이루어진 그룹 중에서 선택된 2종 이상을 조합하여 포함한 것을 특징으로 하는, 피부암 이외의 암을 대상으로 하는 암 예방 및 치료용 조성물.
- 청구항 2에 있어서, 상기 디벤조-p-디옥신 유도체는아이세니아 바시클리스(Eisenia bicyclis), 아이세니아 아르보레아(Eisenia arborea),아이세니아 데스마레스티오데스(Eisenia desmarestioides), 아이세니아 갈라파제니스(Eisenia galapagensis), 아이세니아 매소니(Eisenia masonii), 에클로니아 쿠로메(Ecklonia kurome), 에클로니아 카바(Ecklonia cava), 에클로니아 스톨로니페라(Ecklonia stolonifera), 에클로니아 맥시마(Ecklonia maxima), 에클로니아 라디아타(Ecklonia radiata), 에클로니아 바이시클리스(Ecklonia bicyclis), 에클로니아 바이런시네이트(Ecklonia biruncinate), 에클로니아 부시날리스(Ecklonia buccinalis), 에클로니아 카에파에스팁스(Ecklonia caepaestipes), 에클로니아 엑사스퍼타(Ecklonia exasperta), 에클로니아 파스티기아타(Ecklonia fastigiata), 에클로니아 브레빕스(Ecklonia brevipes), 에클로니아 아라보레아(Ecklonia arborea), 에클로니아 라티폴리아(Ecklonia latifolia), 에클로니아 무라티(Ecklonia muratii), 에클로니아 라디코사(Ecklonia radicosa), 에클로니아 리타디아나(Ecklonia richardiana) 및 에클로니아 라이티(Ecklonia wrightii)로 이루어진 그룹으로부터 선택된 1종 이상으로부터 추출된 것임을 특징으로 하는, 피부암 이외의 암을 대상으로 하는 암예방 또는 치료용 조성물.
- 청구항 2에 있어서, 상기 조성물은 1-100mg/Kg의 일일 섭취량 또는 일일 도포량을 가지는 것을 특징으로 하는, 피부암 이외의 암을 대상으로 하는 암예방 또는 치료용 조성물.
- 청구항 2에 있어서, 상기 조성물은 캡슐 또는 정제 형태를 갖는 것을 특징으로 하는, 피부암 이외의 암을 대상으로 하는 암예방 또는 치료용 조성물.
- 청구항 2 내지 6 중 어느 한 항 기재의 조성물을 포함하는 것을 특징으로 하는 건강보조식품.
- 청구항 8에 있어서, 상기 건강보조식품은 음료, 빵, 캡슐 및 정제 중에서 선택된 어느 하나의 형태인 것을 특징으로 하는 건강보조식품.
- 삭제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060086706A KR100794610B1 (ko) | 2006-09-08 | 2006-09-08 | 디벤조-p-디옥신 유도체를 유효성분으로 하는 암 예방 및치료용 조성물 및 이를 함유하는 건강보조식품 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060086706A KR100794610B1 (ko) | 2006-09-08 | 2006-09-08 | 디벤조-p-디옥신 유도체를 유효성분으로 하는 암 예방 및치료용 조성물 및 이를 함유하는 건강보조식품 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100794610B1 true KR100794610B1 (ko) | 2008-01-14 |
Family
ID=39217765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060086706A KR100794610B1 (ko) | 2006-09-08 | 2006-09-08 | 디벤조-p-디옥신 유도체를 유효성분으로 하는 암 예방 및치료용 조성물 및 이를 함유하는 건강보조식품 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100794610B1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100991398B1 (ko) | 2008-06-27 | 2010-11-02 | 한국과학기술연구원 | 쇠꼬리산말 추출물을 유효성분으로 함유하는 항염증용조성물 |
CN102056604A (zh) * | 2008-06-05 | 2011-05-11 | 来威肯株式会社 | 包含二苯并-对-二恶英衍生物作为活性成分的治疗关节炎的组合物 |
KR20130094901A (ko) * | 2012-02-17 | 2013-08-27 | 주식회사 보타메디 | 항암치료 효과 증강용 조성물 |
KR101309538B1 (ko) | 2010-11-17 | 2013-09-23 | 한양대학교 산학협력단 | 엑콜 화합물을 함유하는 암 줄기세포 성장 억제용 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070017449A (ko) * | 2005-05-16 | 2007-02-12 | 라이브켐 주식회사 | 피부암의 예방 및 치료용 조성물 |
-
2006
- 2006-09-08 KR KR1020060086706A patent/KR100794610B1/ko active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070017449A (ko) * | 2005-05-16 | 2007-02-12 | 라이브켐 주식회사 | 피부암의 예방 및 치료용 조성물 |
Non-Patent Citations (3)
Title |
---|
Joe MJ et al; Biol Pharm Bull. 2006 Aug;29(8):1735-9 |
Kang, Hye-Sook et al; Archives of Pharmacal Research, 2004, 27(2), pp.194-198 |
Kim, Youn-Chul et al; Archives of Pharmacal Research, 2005, 28(12), pp.1376-1380 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102056604A (zh) * | 2008-06-05 | 2011-05-11 | 来威肯株式会社 | 包含二苯并-对-二恶英衍生物作为活性成分的治疗关节炎的组合物 |
KR100991398B1 (ko) | 2008-06-27 | 2010-11-02 | 한국과학기술연구원 | 쇠꼬리산말 추출물을 유효성분으로 함유하는 항염증용조성물 |
KR101309538B1 (ko) | 2010-11-17 | 2013-09-23 | 한양대학교 산학협력단 | 엑콜 화합물을 함유하는 암 줄기세포 성장 억제용 조성물 |
KR20130094901A (ko) * | 2012-02-17 | 2013-08-27 | 주식회사 보타메디 | 항암치료 효과 증강용 조성물 |
KR101945783B1 (ko) * | 2012-02-17 | 2019-02-11 | 주식회사 보타메디 | 항암치료 효과 증강용 조성물 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007119837A1 (ja) | リパーゼ阻害剤 | |
AU2004235702A1 (en) | Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease | |
KR20120023787A (ko) | 대사증후군의 예방제 및/또는 치료제 | |
JP4980429B2 (ja) | アラザイムを有効成分とする癌予防及び治療用組成物 | |
KR100794610B1 (ko) | 디벤조-p-디옥신 유도체를 유효성분으로 하는 암 예방 및치료용 조성물 및 이를 함유하는 건강보조식품 | |
KR20150031780A (ko) | 리그난 화합물을 유효 성분으로 포함하는 암의 예방 또는 치료용 조성물 | |
JP2010070541A (ja) | Tg合成抑制剤 | |
KR20090112955A (ko) | 항염증 활성을 갖는 몰로키아 추출물을 함유하는 식품 | |
KR100902094B1 (ko) | 상백피 추출물, 이의 분획물 및 상기 분획물에서 분리한2―아릴벤조퓨란계 화합물을 유효성분으로 함유하는 암예방 및 치료용 약학적 조성물 | |
US20210386822A1 (en) | Anticancer pharmaceutical composition containing if1 as active ingredient | |
KR20040107185A (ko) | 알란토락톤 또는 이소알란토락톤을 포함하는 암 또는염증질환 예방 및 치료용 조성물 | |
KR101257706B1 (ko) | 오베큐논을 함유하는 혈관질환의 치료 또는 예방용 조성물 | |
KR101794924B1 (ko) | 퉁퉁마디 유래 비알코올성 지방간 질환 예방 또는 치료용 이소람네틴의 분리방법 | |
KR20140082502A (ko) | 테뉴폴리사이드 a를 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물 | |
KR20110035127A (ko) | 곰피와 감태 추출물 유래의 플로로탄닌을 유효성분으로 하는 염증억제용 조성물 | |
KR101332074B1 (ko) | 에스큘레틴을 유효성분으로 함유하는 골 손실 억제용 조성물 | |
KR20180088606A (ko) | 비알코올성 지방간 질환 예방 또는 치료능이 있는 이소람네틴(isorhamnetin)을 함유하는 퉁퉁마디(Salicornia SPP.) 물 추출물의 에틸아세테이트 분획물 | |
US11464787B2 (en) | Composition comprising oleanolic acid acetate as active ingredient for preventing, alleviating, or treating renal toxicity induced by medicine | |
KR101320948B1 (ko) | 야국 추출물을 유효성분으로 포함하는 암의 예방 또는 치료용 조성물 | |
KR101470613B1 (ko) | 라티폴린을 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물 | |
KR101145237B1 (ko) | 디디에이에이치를 활성화시키는 오수유 유래의 알카로이드 화합물 및 이를 유효성분으로 하는 췌장 베타세포 사멸 및 당뇨병성 신증의 예방 또는 치료용 조성물 | |
KR101926021B1 (ko) | 텔렉타디엄 동나이엔스 추출물을 유효성분으로 하는 대장암 예방 또는 치료용 약학 조성물 | |
KR101126957B1 (ko) | 코지산 유도체를 함유하는 항암용 조성물 | |
KR20180000703A (ko) | 비알코올성 지방간 질환 예방 또는 치료능이 있는 이소람네틴 및 염화나트륨을 함유하는 퉁퉁마디 추출물 | |
KR20110062726A (ko) | 캄페라이드 화합물을 유효성분으로 함유하는 항암용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130108 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140108 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150108 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160108 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170109 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180108 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190107 Year of fee payment: 12 |